Baird Financial Group Inc. Has $8.16 Million Stake in IQVIA Holdings Inc. $IQV

Key Points

• Baird Financial Group reduced its IQVIA stake by 21.7% in the second quarter, selling 11,680 shares and retaining 42,219 shares valued at approximately $8.16 million. Institutional investors and hedge funds collectively own 89.62% of the company.
• Analysts remain broadly positive on IQVIA, with a consensus rating of “Moderate Buy” and an average price target of $243.62. JPMorgan and BMO recently raised their targets to $285 and $270, respectively.
• IQVIA exceeded quarterly expectations, reporting $3.15 in adjusted EPS and $4.37 billion in revenue, with revenue up 8.7% year over year. The stock opened at $262.09, near its 52-week high of $271.80, while insiders sold $3.8 million worth of shares over the past three months.

Baird Financial Group Inc. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 21.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,219 shares of the medical research company's stock after selling 11,680 shares during the quarter. Baird Financial Group Inc.'s holdings in IQVIA were worth $8,158,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Financial Freedom LLC bought a new stake in shares of IQVIA in the first quarter worth $25,000. Ascentis Independent Advisors bought a new position in shares of IQVIA in the 1st quarter valued at about $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at about $27,000. Compass Financial Management LLC bought a new stake in IQVIA during the second quarter worth about $27,000. Finally, Gilpin Wealth Management LLC bought a new stake in IQVIA during the fourth quarter worth about $27,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on IQV. Weiss Ratings upgraded shares of IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. raised their target price on shares of IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. BMO Capital Markets boosted their price target on IQVIA from $210.00 to $270.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 29th. William Blair upgraded IQVIA to a "strong-buy" rating in a research note on Tuesday, July 28th. Finally, Barclays reaffirmed an "overweight" rating on shares of IQVIA in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $243.62.

IQVIA Stock Performance

IQV opened at $262.09 on Monday. The business has a fifty day simple moving average of $236.55 and a 200 day simple moving average of $196.16. The company has a market capitalization of $43.14 billion, a PE ratio of 32.52, a price-to-earnings-growth ratio of 2.24 and a beta of 1.18. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $271.80. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. During the same quarter in the previous year, the business posted $2.81 earnings per share. IQVIA's quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

Insider Activity at IQVIA

In related news, insider W. Richard Staub sold 5,500 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares of the company's stock, valued at $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Keriann Cherofsky sold 558 shares of the business's stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares of the company's stock, valued at $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 15,581 shares of company stock valued at $3,796,021. 1.70% of the stock is currently owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.